Promising drug shows hope for Hard-to-Treat prostate cancer
NCT ID NCT04288687
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called niraparib in 11 men with advanced prostate cancer that was no longer responding to hormone therapy but had recently been treated with platinum chemotherapy. The goal was to see if niraparib could keep the cancer from growing for at least 6 months. The approach targets cancers with specific DNA repair defects, aiming to control the disease rather than cure it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can surgery boost control of spread prostate cancer?
- Can a better scan sharpen radiation for prostate cancer?
- Hormone therapy showdown: can an oral pill beat the shot for prostate cancer patients?
- Can tracking tumor movement during radiation make treatment more precise?
- Can a single small incision preserve sexual function after prostate cancer surgery?
- Can a shorter course of radiation tame prostate cancer with fewer side effects?